Moving towards Personalized Medicine in Muscle-Invasive Bladder Cancer: Where Are We Now and Where Are We Going?

Juan Carlos Pardo, Vicenç Ruiz de Porras, Andrea Plaja, Cristina Carrato, Olatz Etxaniz, Oscar Buisan, Albert Font, Juan Carlos Pardo, Vicenç Ruiz de Porras, Andrea Plaja, Cristina Carrato, Olatz Etxaniz, Oscar Buisan, Albert Font

Abstract

Neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy is the recommended treatment, with the highest level of evidence, for patients with muscle-invasive bladder cancer (MIBC). However, only a minority of patients receive this treatment, mainly due to patient comorbidities, the relatively small survival benefit, and the lack of predictive biomarkers to select those patients most likely to benefit from this multimodal approach. In addition, adjuvant chemotherapy has been recommended for patients with high-risk MIBC, although randomized trials have not provided conclusive evidence on the impact of this approach. At present, however, this situation is changing, largely due to our improved knowledge of the molecular biology of bladder cancer, which has enabled us to identify new prognostic and predictive biomarkers that can be used to select the most appropriate treatment for each patient. Moreover, new active treatments, especially immunotherapy, have shown promising results in the neoadjuvant setting. In addition, the gene expression profile of bladder tumors can be used to classify them into different subtypes, which correlate with specific clinical-pathological characteristics and with treatment response or resistance. Therefore, the main objective for the near future is to introduce these translational breakthroughs into routine clinical practice in order to personalize treatment for each patient.

Keywords: chemotherapy; immunotherapy; muscle-invasive bladder cancer; personalized medicine; predictive biomarker.

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Bellmunt J., Fougeray R., Rosenberg J.E., von der Maase H., Schutz F.A., Salhi Y., Culine S., Choueiri T.K. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann. Oncol. 2013;24:1466–1472. doi: 10.1093/annonc/mdt007.
    1. Font A., Luque R., Villa J.C., Domenech M., Vazquez S., Gallardo E., Virizuela J.A., Beato C., Morales-Barrera R., Gelabert A., et al. The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG) Target Oncol. 2019;14:15–32. doi: 10.1007/s11523-019-00619-7.
    1. Alfred Witjes J., Lebret T., Comperat E.M., Cowan N.C., De Santis M., Bruins H.M., Hernandez V., Espinos E.L., Dunn J., Rouanne M., et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur. Urol. 2017;71:462–475. doi: 10.1016/j.eururo.2016.06.020.
    1. Reardon Z.D., Patel S.G., Zaid H.B., Stimson C.J., Resnick M.J., Keegan K.A., Barocas D.A., Chang S.S., Cookson M.S. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: A sign of changing tides. Eur. Urol. 2015;67:165–170. doi: 10.1016/j.eururo.2014.01.009.
    1. Thompson R.H., Boorjian S.A., Kim S.P., Cheville J.C., Thapa P., Tarrel R., Dronca R., Costello B., Frank I. Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients. BJU Int. 2014;113:E17–E21. doi: 10.1111/bju.12274.
    1. Bhindi B., Frank I., Mason R.J., Tarrell R.F., Thapa P., Cheville J.C., Costello B.A., Pagliaro L.C., Karnes R.J., Thompson R.H., et al. Oncologic Outcomes for Patients with Residual Cancer at Cystectomy Following Neoadjuvant Chemotherapy: A Pathologic Stage-matched Analysis. Eur. Urol. 2017;72:660–664. doi: 10.1016/j.eururo.2017.05.016.
    1. Cancer Genome Atlas Research N. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315–322. doi: 10.1038/nature12965.
    1. Hyman D.M., Taylor B.S., Baselga J. Implementing Genome-Driven Oncology. Cell. 2017;168:584–599. doi: 10.1016/j.cell.2016.12.015.
    1. Siddik Z.H. Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22:7265–7279. doi: 10.1038/sj.onc.1206933.
    1. Curtin N.J. DNA repair dysregulation from cancer driver to therapeutic target. Nat. Rev. Cancer. 2012;12:801–817. doi: 10.1038/nrc3399.
    1. Britten R.A., Liu D., Tessier A., Hutchison M.J., Murray D. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int. J. Cancer. 2000;89:453–457. doi: 10.1002/1097-0215(20000920)89:5<453::AID-IJC9>;2-E.
    1. Bellmunt J., Paz-Ares L., Cuello M., Cecere F.L., Albiol S., Guillem V., Gallardo E., Carles J., Mendez P., de la Cruz J.J., et al. Spanish Oncology Genitourinary, G. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann. Oncol. 2007;18:522–528. doi: 10.1093/annonc/mdl435.
    1. Pietzak E.J., Zabor E.C., Bagrodia A., Armenia J., Hu W., Zehir A., Funt S., Audenet F., Barron D., Maamouri N., et al. Genomic Differences Between “Primary” and “Secondary” Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. Eur. Urol. 2019;75:231–239. doi: 10.1016/j.eururo.2018.09.002.
    1. Van Allen E.M., Mouw K.W., Kim P., Iyer G., Wagle N., Al-Ahmadie H., Zhu C., Ostrovnaya I., Kryukov G.V., O’Connor K.W., et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 2014;4:1140–1153. doi: 10.1158/-14-0623.
    1. Liu D., Plimack E.R., Hoffman-Censits J., Garraway L.A., Bellmunt J., Van Allen E., Rosenberg J.E. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2:1094–1096. doi: 10.1001/jamaoncol.2016.1056.
    1. Plimack E.R., Dunbrack R.L., Brennan T.A., Andrake M.D., Zhou Y., Serebriiskii I.G., Slifker M., Alpaugh K., Dulaimi E., Palma N., et al. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. Eur. Urol. 2015;68:959–967. doi: 10.1016/j.eururo.2015.07.009.
    1. Miron B., Hoffman-Censits J.H., Anari F., O’Neill J., Geynisman D.M., Zibelman M.R., Kutikov A., Viterbo R., Greenberg R.E., Chen D., et al. Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur. Urol. Oncol. 2020 doi: 10.1016/j.euo.2020.02.003.
    1. Heeke A.L., Pishvaian M.J., Lynce F., Xiu J., Brody J.R., Chen W.J., Baker T.M., Marshall J.L., Isaacs C. Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types. JCO Precis. Oncol. 2018;2018 doi: 10.1200/PO.17.00286.
    1. Carlo M.I., Ravichandran V., Srinavasan P., Bandlamudi C., Kemel Y., Ceyhan-Birsoy O., Mukherjee S., Mandelker D., Chaim J., Knezevic A., et al. Cancer Susceptibility Mutations in Patients with Urothelial Malignancies. J. Clin. Oncol. 2020;38:406–414. doi: 10.1200/JCO.19.01395.
    1. Font A., Taron M., Gago J.L., Costa C., Sanchez J.J., Carrato C., Mora M., Celiz P., Perez L., Rodriguez D., et al. BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. Ann. Oncol. 2011;22:139–144. doi: 10.1093/annonc/mdq333.
    1. Teo M.Y., Bambury R.M., Zabor E.C., Jordan E., Al-Ahmadie H., Boyd M.E., Bouvier N., Mullane S.A., Cha E.K., Roper N., et al. DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. Clin. Cancer Res. 2017;23:3610–3618. doi: 10.1158/1078-0432.CCR-16-2520.
    1. Iyer G., Balar A.V., Milowsky M.I., Bochner B.H., Dalbagni G., Donat S.M., Herr H.W., Huang W.C., Taneja S.S., Woods M., et al. Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients with Muscle-Invasive Bladder Cancer. J. Clin. Oncol. 2018;36:1949–1956. doi: 10.1200/JCO.2017.75.0158.
    1. Romeo M., Pardo J.C., Martinez-Cardus A., Martinez-Balibrea E., Quiroga V., Martinez-Roman S., Sole F., Margeli M., Mesia R. Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer. Int. J. Mol. Sci. 2018;19:3249. doi: 10.3390/ijms19103249.
    1. Sjodahl G., Lauss M., Lovgren K., Chebil G., Gudjonsson S., Veerla S., Patschan O., Aine M., Ferno M., Ringner M., et al. A molecular taxonomy for urothelial carcinoma. Clin. Cancer Res. 2012;18:3377–3386. doi: 10.1158/1078-0432.CCR-12-0077-T.
    1. Damrauer J.S., Hoadley K.A., Chism D.D., Fan C., Tiganelli C.J., Wobker S.E., Yeh J.J., Milowsky M.I., Iyer G., Parker J.S., et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc. Natl. Acad. Sci. USA. 2014;111:3110–3115. doi: 10.1073/pnas.1318376111.
    1. Choi W., Porten S., Kim S., Willis D., Plimack E.R., Hoffman-Censits J., Roth B., Cheng T., Tran M., Lee I.L., et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25:152–165. doi: 10.1016/j.ccr.2014.01.009.
    1. Robertson A.G., Kim J., Al-Ahmadie H., Bellmunt J., Guo G., Cherniack A.D., Hinoue T., Laird P.W., Hoadley K.A., Akbani R., et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2018;174:1033. doi: 10.1016/j.cell.2018.07.036.
    1. Seiler R., Ashab H.A.D., Erho N., van Rhijn B.W.G., Winters B., Douglas J., Van Kessel K.E., Fransen van de Putte E.E., Sommerlad M., Wang N.Q., et al. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. Eur. Urol. 2017;72:544–554. doi: 10.1016/j.eururo.2017.03.030.
    1. Kamoun A., de Reynies A., Allory Y., Sjodahl G., Robertson A.G., Seiler R., Hoadley K.A., Groeneveld C.S., Al-Ahmadie H., Choi W., et al. Bladder Cancer Molecular Taxonomy, G. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur. Urol. 2020;77:420–433. doi: 10.1016/j.eururo.2019.09.006.
    1. Lotan Y., Boorjian S.A., Zhang J., Bivalacqua T.J., Porten S.P., Wheeler T., Lerner S.P., Hutchinson R., Francis F., Davicioni E., et al. Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors. Eur. Urol. 2019;76:200–206. doi: 10.1016/j.eururo.2019.04.036.
    1. Warrick J.I., Sjodahl G., Kaag M., Raman J.D., Merrill S., Shuman L., Chen G., Walter V., DeGraff D.J. Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants. Eur. Urol. 2019;75:18–22. doi: 10.1016/j.eururo.2018.09.003.
    1. Dadhania V., Zhang M., Zhang L., Bondaruk J., Majewski T., Siefker-Radtke A., Guo C.C., Dinney C., Cogdell D.E., Zhang S., et al. Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use. EBioMedicine. 2016;12:105–117. doi: 10.1016/j.ebiom.2016.08.036.
    1. Makboul R., Hassan H.M., Refaiy A., Abdelkawi I.F., Shahat A.A., Hameed D.A., Morsy A., Salah T., Ahmed Mohammed R.A. A Simple Immunohistochemical Panel Could Predict and Correlate to Clinicopathologic and Molecular Subgroups of Urinary Bladder Urothelial Carcinoma. Clin. Genitourin Cancer. 2019;17:e712–e719. doi: 10.1016/j.clgc.2019.04.011.
    1. McConkey D.J., Choi W., Shen Y., Lee I.L., Porten S., Matin S.F., Kamat A.M., Corn P., Millikan R.E., Dinney C., et al. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naive Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. Eur. Urol. 2016;69:855–862.
    1. Seiler R., Gibb E.A., Wang N.Q., Oo H.Z., Lam H.M., van Kessel K.E., Voskuilen C.S., Winters B., Erho N., Takhar M.M., et al. Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer. Clin. Cancer Res. 2019;25:5082–5093. doi: 10.1158/1078-0432.CCR-18-1106.
    1. Font A., Domenech M., Benitez R., Rava M., Marques M., Ramirez J.L., Pineda S., Dominguez-Rodriguez S., Gago J.L., Badal J., et al. Immunohistochemistry-Based Taxonomical Classification of Bladder Cancer Predicts Response to Neoadjuvant Chemotherapy. Cancers. 2020;12:1784
    1. Rosenberg J.E., Hoffman-Censits J., Powles T., van der Heijden M.S., Balar A.V., Necchi A., Dawson N., O’Donnell P.H., Balmanoukian A., Loriot Y., et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909–1920. doi: 10.1016/S0140-6736(16)00561-4.
    1. Sharma P., Retz M., Siefker-Radtke A., Baron A., Necchi A., Bedke J., Plimack E.R., Vaena D., Grimm M.O., Bracarda S., et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18:312–322. doi: 10.1016/S1470-2045(17)30065-7.
    1. Kardos J., Chai S., Mose L.E., Selitsky S.R., Krishnan B., Saito R., Iglesia M.D., Milowsky M.I., Parker J.S., Kim W.Y., et al. Claudin-low bladder tumors are immune infiltrated and actively immune suppressed. JCI Insight. 2016;1:e85902. doi: 10.1172/jci.insight.85902.
    1. Kim J., Kwiatkowski D., McConkey D.J., Meeks J.J., Freeman S.S., Bellmunt J., Getz G., Lerner S.P. The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability. Eur. Urol. 2019;75:961–964. doi: 10.1016/j.eururo.2019.02.017.
    1. Mariathasan S., Turley S.J., Nickles D., Castiglioni A., Yuen K., Wang Y., Kadel E.E., III, Koeppen H., Astarita J.L., Cubas R., et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544–548. doi: 10.1038/nature25501.
    1. Hussain S.A., Birtle A., Crabb S., Huddart R., Small D., Summerhayes M., Jones R., Protheroe A. From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma. Eur. Urol. Oncol. 2018;1:486–500. doi: 10.1016/j.euo.2018.05.011.
    1. Boorjian S.A., Sheinin Y., Crispen P.L., Farmer S.A., Lohse C.M., Kuntz S.M., Leibovich B.C., Kwon E.D., Frank I. T-cell coregulatory molecule expression in urothelial cell carcinoma: Clinicopathologic correlations and association with survival. Clin. Cancer Res. 2008;14:4800–4808. doi: 10.1158/1078-0432.CCR-08-0731.
    1. Aggen D.H., Drake C.G. Biomarkers for immunotherapy in bladder cancer: A moving target. J. Immunother. Cancer. 2017;5:94. doi: 10.1186/s40425-017-0299-1.
    1. Ayers M., Lunceford J., Nebozhyn M., Murphy E., Loboda A., Kaufman D.R., Albright A., Cheng J.D., Kang S.P., Shankaran V., et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Investig. 2017;127:2930–2940. doi: 10.1172/JCI91190.
    1. Teo M.Y., Seier K., Ostrovnaya I., Regazzi A.M., Kania B.E., Moran M.M., Cipolla C.K., Bluth M.J., Chaim J., Al-Ahmadie H., et al. Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. J. Clin. Oncol. 2018;36:1685–1694. doi: 10.1200/JCO.2017.75.7740.
    1. Le D.T., Uram J.N., Wang H., Bartlett B.R., Kemberling H., Eyring A.D., Skora A.D., Luber B.S., Azad N.S., Laheru D., et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N. Engl. J. Med. 2015;372:2509–2520. doi: 10.1056/NEJMoa1500596.
    1. van Dijk N., Funt S.A., Blank C.U., Powles T., Rosenberg J.E., van der Heijden M.S. The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer. Eur. Urol. 2019;75:435–444. doi: 10.1016/j.eururo.2018.09.022.
    1. Versluis J.M., Long G.V., Blank C.U. Learning from clinical trials of neoadjuvant checkpoint blockade. Nat. Med. 2020;26:475–484. doi: 10.1038/s41591-020-0829-0.
    1. Necchi A., Anichini A., Raggi D., Briganti A., Massa S., Luciano R., Colecchia M., Giannatempo P., Mortarini R., Bianchi M., et al. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. J. Clin. Oncol. 2018;36:3353–3360. doi: 10.1200/JCO.18.01148.
    1. Powles T., Kockx M., Rodriguez-Vida A., Duran I., Crabb S.J., Van Der Heijden M.S., Szabados B., Pous A.F., Gravis G., Herranz U.A., et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat. Med. 2019;25:1706–1714. doi: 10.1038/s41591-019-0628-7.
    1. Efstathiou J.A., Mouw K.W., Gibb E.A., Liu Y., Wu C.L., Drumm M.R., da Costa J.B., du Plessis M., Wang N.Q., Davicioni E., et al. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer. Eur. Urol. 2019;76:59–68. doi: 10.1016/j.eururo.2019.01.011.
    1. Necchi A., Raggi D., Gallina A., Ross J.S., Fare E., Giannatempo P., Marandino L., Colecchia M., Luciano R., Bianchi M., et al. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer. Eur. Urol. 2020;77:701–710. doi: 10.1016/j.eururo.2020.02.028.
    1. Krantz D., Hartana C.A., Winerdal M.E., Johansson M., Alamdari F., Jakubczyk T., Huge Y., Aljabery F., Palmqvist K., Zirakzadeh A.A., et al. Neoadjuvant Chemotherapy Reinforces Antitumour T cell Response in Urothelial Urinary Bladder Cancer. Eur. Urol. 2018;74:688–692. doi: 10.1016/j.eururo.2018.06.048.
    1. Galsky M.D., Arija J.A.A., Bamias A., Davis I.D., De Santis M., Kikuchi E., Garcia-Del-Muro X., De Giorgi U., Mencinger M., Izumi K., et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): A multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395:1547–1557. doi: 10.1016/S0140-6736(20)30230-0.
    1. Voorwerk L., Slagter M., Horlings H.M., Sikorska K., van de Vijver K.K., de Maaker M., Nederlof I., Kluin R.J.C., Warren S., Ong S., et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: The TONIC trial. Nat. Med. 2019;25:920–928. doi: 10.1038/s41591-019-0432-4.
    1. Hussain M.H.A., Powles T., Albers P., Castellano D., Daneshmand S., Gschwend J., Nishiyama H., Oudard S., Tayama D., Davarpanah N.N., et al. IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC) J. Clin. Oncol. 2020;38:5000. doi: 10.1200/JCO.2020.38.15_suppl.5000.

Source: PubMed

3
購読する